Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cyclobenzaprine hydrochloride very low dose - Tonix Pharmaceuticals

Drug Profile

Cyclobenzaprine hydrochloride very low dose - Tonix Pharmaceuticals

Alternative Names: Cyclobenzaprine HCL; Cyclobenzaprine hydrochloride - Tonix Pharmaceuticals; KRL-102; TNX-102; TNX-102 SL; Tonmya; VLD-cyclobenzaprine

Latest Information Update: 13 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vela Pharmaceuticals
  • Developer Tonix Pharmaceuticals Holding Corp; Tonix Pharmaceuticals Inc
  • Class Amines; Analgesics; Anxiolytics; Behavioural disorder therapies; Dibenzocycloheptenes; Drug withdrawal therapies; Muscle relaxants; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Histamine H1 receptor antagonists; Muscarinic M1 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Fibromyalgia; Post-traumatic stress disorders
  • Phase II Agitation; Post acute COVID 19 syndrome
  • Preclinical Alcoholism
  • No development reported Unspecified

Most Recent Events

  • 04 Jan 2023 Phase-II clinical trials in Post-traumatic stress disorders in Kenya (Sublingual) (NCT05372887)
  • 07 Nov 2022 Tonix Pharmaceuticals plans a phase II trial in Post traumatic stress disorder (In adults, In the elderly) in Kenya in fourth quarter of 2022 (Sublingual) (NCT05372887)
  • 28 Aug 2022 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in Canada (Sublingual, Tablet)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top